BRPI0407615A - curativo trans-dérmico estável a uv - Google Patents

curativo trans-dérmico estável a uv

Info

Publication number
BRPI0407615A
BRPI0407615A BRPI0407615-0A BRPI0407615A BRPI0407615A BR PI0407615 A BRPI0407615 A BR PI0407615A BR PI0407615 A BRPI0407615 A BR PI0407615A BR PI0407615 A BRPI0407615 A BR PI0407615A
Authority
BR
Brazil
Prior art keywords
layer
active substance
absorber
matrix
stable transdermal
Prior art date
Application number
BRPI0407615-0A
Other languages
English (en)
Inventor
Jochen Schumacher
Manfred Suesse
Michael Dittgen
Stephan Mletzko
Jan-Peter Ingwersen
Thomas Langguth
Dirk Schenk
Hubert Kaffl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0407615A publication Critical patent/BRPI0407615A/pt
Publication of BRPI0407615B1 publication Critical patent/BRPI0407615B1/pt
Publication of BRPI0407615B8 publication Critical patent/BRPI0407615B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

"CURATIVO TRANS-DéRMICO ESTáVEL A UV". A invenção refere-se a um novo sistema terapêutico transdérmico estável a UV (TTS), que consiste de uma camada de reforço, pelo menos uma matriz contendo substância ativa, e opcionalmente um filme destacável assim como um absorvedor de UV, sendo que uma camada adesiva contendo o referido absorvedor de UV, entre a camada de reforço e a superfície da pele, está prevista na matriz contendo uma substância ativa que está o mais distante possível da superfície da pele, uma camada de separação é disposta entre a camada adesiva contendo o referido absorvedor de radiação UV e a matriz contendo uma substância ativa. O sistema terapêutico trans-dérmico de acordo com a invenção exibe uma elevada estabilidade sem as inconveniências de TTS contendo substâncias ativas sensíveis à luz.
BRPI0407615A 2003-02-21 2004-02-04 sistema terapêutico transdérmico estável à radiação ultravioleta BRPI0407615B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03003888.9 2003-02-21
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster
EP03004061.2 2003-02-25
PCT/EP2004/001052 WO2004073696A1 (de) 2003-02-21 2004-02-04 Uv-stabiles transdermales pflaster

Publications (3)

Publication Number Publication Date
BRPI0407615A true BRPI0407615A (pt) 2006-02-14
BRPI0407615B1 BRPI0407615B1 (pt) 2018-02-14
BRPI0407615B8 BRPI0407615B8 (pt) 2021-05-25

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407615A BRPI0407615B8 (pt) 2003-02-21 2004-02-04 sistema terapêutico transdérmico estável à radiação ultravioleta

Country Status (31)

Country Link
US (3) US8486443B2 (pt)
EP (1) EP1594483B1 (pt)
JP (1) JP4528296B2 (pt)
KR (1) KR100704825B1 (pt)
AR (1) AR043248A1 (pt)
AT (1) ATE333271T1 (pt)
AU (1) AU2004212675B2 (pt)
BR (1) BRPI0407615B8 (pt)
CA (1) CA2515918C (pt)
CR (1) CR7952A (pt)
CY (1) CY1105716T1 (pt)
DE (1) DE502004000988D1 (pt)
DK (1) DK1594483T3 (pt)
EA (1) EA008098B1 (pt)
EC (1) ECSP056030A (pt)
ES (1) ES2270345T3 (pt)
HK (1) HK1085394A1 (pt)
HR (1) HRP20050828B1 (pt)
IL (1) IL170295A (pt)
IS (1) IS2541B (pt)
ME (2) MEP14008A (pt)
MX (1) MXPA05008778A (pt)
NO (1) NO336108B1 (pt)
NZ (1) NZ541807A (pt)
PE (1) PE20041028A1 (pt)
PL (1) PL219030B1 (pt)
PT (1) PT1594483E (pt)
RS (1) RS50428B (pt)
SI (1) SI1594483T1 (pt)
UY (1) UY28189A1 (pt)
WO (1) WO2004073696A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE333271T1 (de) 2003-02-21 2006-08-15 Schering Ag Uv-stabiles transdermales pflaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
CA2730498A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
DK2613772T3 (en) * 2010-09-06 2017-03-06 Bayer Ip Gmbh TRANSDERMAL LOW DOSAGE PATTERNS WITH HIGH PHARMACEUTICAL RELEASE
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180127315A (ko) 2015-12-30 2018-11-28 코리움 인터네셔널, 인크. 장기 경피 투여를 위한 시스템 및 방법
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (pt) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) * 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) * 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
WO1990004397A1 (de) * 1988-10-27 1990-05-03 Schering Aktiengesellschaft Berlin Und Bergkamen Mittel zur transdermalen applikation enthaltend gestoden
EP0453396B1 (de) * 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
DE69108512T2 (de) 1990-05-17 1995-08-03 Hisamitsu Pharmaceutical Co Estradiol enthaltende transdermale zubereitung.
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
WO1992007590A1 (en) 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) * 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
AU692944B2 (en) 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
ES2190472T5 (es) * 1995-06-07 2012-03-09 Ortho-Mcneil Pharmaceutical, Inc. Parche transdérmico para la administración de 17-deacetil norgestimato, en combinación con un estrógeno.
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
CN1252004A (zh) 1997-04-16 2000-05-03 久光制药株式会社 经皮吸收用基质组合物及含有该基质组合物的可经皮吸收的制剂
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
WO2000045798A1 (en) 1999-02-02 2000-08-10 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
KR20010112479A (ko) 1999-07-01 2001-12-20 나까도미 히로다카 경피흡수 첩부제
IL149655A0 (en) 1999-11-24 2002-11-10 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CN1245961C (zh) 2000-03-17 2006-03-22 久光制药株式会社 紫外遮蔽性贴剂
WO2001095889A1 (fr) * 2000-06-13 2001-12-20 Hisamitsu Pharmaceutical Co., Inc. Platre
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
CA2478206A1 (en) 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) * 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ATE333271T1 (de) 2003-02-21 2006-08-15 Schering Ag Uv-stabiles transdermales pflaster
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
EP1660294B1 (en) * 2003-08-25 2008-12-03 BFS Diversified Products, LLC Method and apparatus to monitor the compressive strength of insulation boards
AU2004270402A1 (en) * 2003-09-11 2005-03-17 Ciba Specialty Chemicals Holding Inc. Water based concentrated product forms of light stabilizers made by a heterophase polymerization technique
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
MXPA06006682A (es) 2003-12-12 2006-08-11 Schering Ag Hormonas de administracion transdermica que no necesitan potenciadores de penetracion.
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
KR20110082142A (ko) 2008-10-06 2011-07-18 밀란 테크놀로지즈 인코포레이티드 비정질 로티고틴 경피 시스템

Also Published As

Publication number Publication date
DK1594483T3 (da) 2006-11-20
SI1594483T1 (sl) 2006-12-31
RS20050639A (en) 2007-09-21
MXPA05008778A (es) 2006-05-25
AU2004212675A1 (en) 2004-09-02
NZ541807A (en) 2009-07-31
IS8031A (is) 2005-09-15
IL170295A (en) 2010-05-31
PL219030B1 (pl) 2015-03-31
CA2515918C (en) 2010-11-16
BRPI0407615B8 (pt) 2021-05-25
EA200501224A1 (ru) 2006-04-28
AR043248A1 (es) 2005-07-20
JP4528296B2 (ja) 2010-08-18
CY1105716T1 (el) 2010-12-22
EP1594483A1 (de) 2005-11-16
PT1594483E (pt) 2006-12-29
IS2541B (is) 2009-09-15
PL378035A1 (pl) 2006-02-20
US20130226113A1 (en) 2013-08-29
EP1594483B1 (de) 2006-07-19
ATE333271T1 (de) 2006-08-15
JP2006518348A (ja) 2006-08-10
WO2004073696A1 (de) 2004-09-02
KR20050103499A (ko) 2005-10-31
ECSP056030A (es) 2006-01-27
MEP14008A (en) 2010-06-10
ME00147B (me) 2010-10-10
US20060251707A1 (en) 2006-11-09
HRP20050828A2 (en) 2006-03-31
US9095691B2 (en) 2015-08-04
HK1085394A1 (en) 2006-08-25
US8486443B2 (en) 2013-07-16
KR100704825B1 (ko) 2007-04-09
CA2515918A1 (en) 2004-09-02
HRP20050828B1 (hr) 2013-10-25
ES2270345T3 (es) 2007-04-01
UY28189A1 (es) 2004-04-30
US20150335658A1 (en) 2015-11-26
DE502004000988D1 (de) 2006-08-31
CR7952A (es) 2006-02-06
BRPI0407615B1 (pt) 2018-02-14
NO336108B1 (no) 2015-05-18
RS50428B (sr) 2009-12-31
AU2004212675B2 (en) 2006-06-01
EA008098B1 (ru) 2007-02-27
PE20041028A1 (es) 2005-02-18
NO20054321L (no) 2005-09-20

Similar Documents

Publication Publication Date Title
BRPI0407615A (pt) curativo trans-dérmico estável a uv
ATE95711T1 (de) Therapeutisches system zur transdermalen oder transmucosalen verabreichung von wirkstoffen und seine verwendung.
BRPI0503910A (pt) sistema e método para dispositivo de display com substáncia de reforço
AR097045A2 (es) Sistema terapéutico transdérmico
BR0212026A (pt) Sistema terapêutico transdérmico com fentanila ou substâncias análogas
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
CY1115757T1 (el) Στερεο διαδερμικο θεραπευτικο συστημα που περιλαμβανει uv-απορροφητη
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
TH87440B (th) ระบบรักษาโรคผ่านทางผิวหนังชนิดของแข็งที่มีสารดูดกลืนยูวี
TH87440A (th) ระบบรักษาโรคผ่านทางผิวหนังชนิดของแข็งที่มีสารดูดกลืนยูวี
ES2159459B1 (es) Placa de construccion transparente.
AR022956A1 (es) Sistema transdermal terapeutico y procedimiento para su fabricacion
AR037405A1 (es) Sistema terapeutico transdermal para la administracion de 17alfa-estradiol
BR0201044A (pt) Pelìcula protetora para telefones públicos
UY26644A1 (es) Pequenas esferas o glóbulos que contienen estavudina y permiten la liberación controlada de la misma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2708 DE 29-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.